Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: 1years to less than 5 years for the younger children group; 5- less than18 years for older children and adolescent group and 18- 45 years (inclusive) for the adult group.~2. Sex: Male, Female, Transgender.~3. Consent: Informed consent from study participants and guardian in case of children along with assent in children 11-17 years (inclusive) of age.~4. Apparently healthy.~Exclusion Criteria:~1. Suffering from diarrhoea or abdominal pain or vomiting in the past 24 hours or diarrhoea lasting for more than 2 weeks in the past 6 months~2. History of taking oral cholera vaccine.~3. History of taking any other live or killed enteric vaccine in the last 8 weeks.~4. History of anaphylaxis or serious vaccine reaction.~5. Currently use of any immunosuppressive or immune-modifying drugs.~6. Receipt of blood or blood products or parenteral immunoglobulin preparation in the past 3 months.~7. Currently on antimicrobial therapy (taking antibiotics within 24 hours during screening and vaccination).~8. Severe malnutrition defined as wt-for-ht z-score \<-3.0 with or without oedema.~9. For married females pregnancy or plans to become pregnant during the study period (as determined by verbal screening) will be excluded. In addition, pregnancy test will be done by pregnancy strip test before each day of vaccination (Day 0 and day 14) for married female.~10. Culture positive V. cholerae, ETEC, Salmonella and Shigella in stool.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- HL-OCV (Type: EXPERIMENTAL): Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
- Shanchol (Type: ACTIVE_COMPARATOR): The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).